The prognostic and clinicopathological significance of SLC7A11 in human cancers: a systematic review and meta-analysis.

Jiantao Wang, Siyuan Hao, Guojiao Song, Yan Wang, Qiukui Hao

PeerJ 2023

filter terms:

It is of great importance to recognize bio-markers for cancer prognosis. However, the association between solute carrier family 7 member 11 (SLC7A11) and prognosis is still controversial. Therefore, we conducted this systematic review and meta-analysis to identify the prognostic and clinicopathological significance of SLC7A11 in human cancers. PubMed, Web of Science, Scopus, the Cochrane Library and Embase database were searched from database inceptions to March 19th 2022. Hand searches were also conducted in references. Prognosis and clinicopathological data were extracted and analyzed. A total of 12 eligible studies with 1,955 patients were included. The results indicated that SLC7A11 expression is associated with unfavorable overall survival (OS), unfavorable recurrence-free survival (RFS) and unfavorable progression free survival (PFS). And SLC7A11 expression is also associated with more advanced tumor stage. SLC7A11 expression is associated with more unfavorable prognosis and more advanced tumor stage. Therefore, SLC7A11 could be a potential biomarker for human cancer prognosis. ©2023 Wang et al.

Citation

Jiantao Wang, Siyuan Hao, Guojiao Song, Yan Wang, Qiukui Hao. The prognostic and clinicopathological significance of SLC7A11 in human cancers: a systematic review and meta-analysis. PeerJ. 2023;11:e14931